A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2030

Conditions
HER2-positive Breast CancerInvasive Carcinoma of the BreastBreast CancerNode Negative Breast CancerMicrometastasis Breast CancerHormone Receptor Positive Breast Cancer
Interventions
COMBINATION_PRODUCT

Pertuzumab+TRASTUZUMAB

Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose

DRUG

ADJUVANT ENDOCRINE THERAPY

Oral, daily per cycle

Trial Locations (32)

10016

RECRUITING

New York University Langone Health, New York

11220

RECRUITING

New York University Langone Hospital -Brooklyn, Brooklyn

11501

RECRUITING

New York University Langone Hospital - Long Island, Mineola

27518

RECRUITING

UNC Rex Hematology Oncology Associated - Cary, Cary

27529

RECRUITING

UNC Rex Hematology Oncology Associates of Garner, Garner

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

27607

RECRUITING

UNC Rex Cancer Center, Raleigh

27614

RECRUITING

UNC Rex Cancer Center at Wakefield, Raleigh

30308

RECRUITING

Winship Cancer Institute at Emory University Hospital Midtown, Atlanta

30322

RECRUITING

Emory University - Winship Cancer Institute, Atlanta

30342

RECRUITING

Winship Cancer Institute at Emory Saint Joseph's Hospital, Atlanta

33136

RECRUITING

University of Miami- Sylvester Comprehensive Cancer Center, Miami

37203

RECRUITING

Sarah Cannon Research Institute/Tennessee Oncology, Nashville

RECRUITING

SCRI Oncology Partners, Nashville

RECRUITING

Vanderbilt University Medical Center, Nashville

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

45219

RECRUITING

The Christ Hospital, Cincinnati

46032

RECRUITING

Indiana University Health Schwarz Cancer Center, Indianapolis

46202

RECRUITING

Indiana University Health - Melvin and Bren Simon Cancer Center, Indianapolis

RECRUITING

Indiana University Sidney and Lois Eskenazi Hospital, Indianapolis

60637

RECRUITING

University of Chicago Medical Center, Chicago

77030

RECRUITING

Baylor College of Medicine Medical Center, Houston

RECRUITING

MD Anderson Cancer Center, Houston

06904

RECRUITING

Stamford Hospital, Stamford

04412

RECRUITING

Eastern Maine Medical Center (Northern Light), Brewer

02115

RECRUITING

Dana Farber Cancer Institite, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

02035

RECRUITING

Dana-Farber Brigham Cancer Center - Foxborough, Foxborough

02601

RECRUITING

Cape Cod Healthcare Center, Hyannis

01757

RECRUITING

Dana-Farber at Milford, Milford

02190

RECRUITING

Dana-Farber at South Shore Hospital, Weymouth

03053

RECRUITING

Dana-Farber Cancer Insitute at Londonderry Hospital, Londonderry

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER